Rayno Life Science Portfolios With Sector Up 20% YTD 6/20/13
Rayno Diagnostics and Tools Portfolio Prices as of 5/29/13 Top 2013 Winners: ABAX, ALR, CSII, GHDX, ILMN, TMO, VRML Sector high was in mid-May Less volatile than biopharma but more dependent on earnings Five companies on focus list were acquired over 3 years 2010-2013 Original Price Price %...
FED No Change: Market Down 1% as Less Monetary Accommodation Likely in Future
Downside Risk to Economy Diminished So Less "Extreme Monetary Policy" In the Future? Market Stable with downward bias :S&P flat to down 18 pts-10 Year Bond Yield At 2.28% up 3.9% FED Is Optimistic about the economy: housing, consumer sentiment, financial backdrop but with fiscal drag. Bond...
Biotech Bull Market Momentum is Easing So Watch High Flyers: AEGR,CLVS etc- Update 6/16
Biotech Sell-Off Continues Nothing dramatic but the overall weakness in biopharmaceutical stocks is continuing today despite a strong performance by NASDAQ up 1.2% at 3464. With biotech having one of it best years of all time, profit taking is expected. The most popular ETFs IBB down 0.4% and...
Rayno Diagnostics and Tools Update: MYGN, SQNM Update 2 June 14
6/14 Supreme Court Ruling on Genetic Tests Takes Down Myriad Stock (MYGN $30.50)-Off Another 3% but still up 13% YTD. The Supreme Court ruling opens up competition for Myriad's breast cancer tests as well as other genetic disease markers.The immediate reaction to the stock was initially...
Choppy Market with Macro in Forefront: Currency, Turkey, iRates
Life Science Stocks Holding Up Amidst Volatility-Stay Cautious Biotech stocks are mixed today as volatility from currency moves and violence in Turkey and the Middle East gives pause to investors. Bonds have corrected almost 5% prompting an exit from bond funds as the 10 Year Treasury hits the...